News Focus
News Focus
Followers 63
Posts 4666
Boards Moderated 0
Alias Born 04/23/2013

Re: Whalatane post# 386298

Monday, 08/15/2022 6:23:15 AM

Monday, August 15, 2022 6:23:15 AM

Post# of 447919
MITIGATE: While the SA author failed to mention MITIGATE, keep in mind that the CVD outcomes measures in the trial are only tertiary. While they may prove valuable, the more valuable Primary & Secondary OC measures are what will drive BP interest in VASCEPA.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News